Siemens Healthineers Profit Rises on Revenue Growth
By Adria Calatayud
Siemens Healthineers reported a rise in net profit for the first quarter of fiscal 2024, helped by higher sales driven by growth in its Varian radiation-oncology business.
Net profit for the quarter to December amounted to 431 million euros ($466.3 million) compared with EUR421 million in the same period a year before, the German healthcare-equipment company said.
Revenue rose to EUR5.18 billion from EUR5.08 billion. Revenue was up 5.7% on a comparable basis, with rises in Varian and the company's imaging and advanced-therapies segments offsetting a drop in diagnostics sales.
Adjusted earnings before interest and taxes grew to EUR742 million from EUR685 million, while the margin expanded to 14.3% from 13.5%.
Analysts had expected Siemens Healthineers to report a net profit of EUR395 million, adjusted EBIT of EUR742 million and revenue of EUR5.11 billion, according to consensus estimates provided by the company.
The company reiterated its guidance for the year ending in September.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
February 01, 2024 01:16 ET (06:16 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks